ScreenPoint Medical is showcasing a new FDA clearance for innovative new capabilities of its industry leading Breast AI Transpara here at the 110th Annual Radiological Society of North America (RSNA) meeting, December 1-4, 2024 (South Hall #5316). The most clinically validated Breast AI on the market, Transpara provides radiologists with a ’second pair‘ of eyes to help detect cancers earlier and reduce recall rates.
ScreenPoint will highlight its latest advancements, which include Transpara 2.1: an updated algorithm based on additional training and insights gathered from luminary users around the world. Transpara 2.1 is compatible with options for breast density (BIRADS and volumetric) and temporal comparison. Allowing suspicious areas on a current study to be analyzed against up to 3 priors over 6 years, the robust temporal comparison capability will be the first of its kind in the market. The Transpara 2.1 algorithm is both CE marked and FDA cleared.
With the algorithm improvements, the system standalone performance is demonstrated to be in the top 10% of radiologists in a presentation by Alejandro Rodriguez Ruiz, PhD at ECR 2024.
